Clinical trials / NCT06852079
Recruiting

Safety & Efficacy of Qurs e Fishar in Mild to Moderate Hypertensive Patients in Pakistan

The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted…

ClinicalTrials.gov IDNCT06852079
PhasePHASE3
Enrollment119
SponsorAbdul Bari
Age30 Years
SexALL
I'm interested View official listing

Conditions studied

Hypertension

About this study

The herbal medicine Qurs-e-Fishar to treat mild to moderate High blood pressure or hypertension comprises of Rauwolfia serpentina. A product of Hamdard Laboratories (Waqf) Pakistan. A Phase III Safety \& Efficacy Open-label, Single-Arm, Interventional, Multicenter, Study in mild to moderate hypertensive, adults (30 to 60 years of age) prescribed with study product for 12 weeks (84 days). Primary End Points: 1. Reduction in diastolic blood pressure less than 130 / 80 mmHg at the end of the study period (accepted by WHO) or if there was a fall of 20 / 10 mmHg or more in diastolic blood pressure as compared to baseline. 2. Type, frequency and severity of ADRs during the study period. Secondary End Points: 1\. Compliance of the prescribed study medication.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Ability to sign ICD * Participant(s) are willing and able to fulfill the requirements of the study protocol * Mild to moderate hypertensive * Mild hypertension range (140-159/90-99 mm Hg) * Moderate hypertension range (160-179/100-109 mm Hg) * Be between the age of 30 to 60 year Exclusion Criteria: * Patients with recent history of following will be excluded: * Severe hypertension, * Congestive cardiac failure, * Left ventricular failure, * Myocardial ischemia, * Renal failure or * Cerebrovascular accidents

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.